The initiation of coverage by Ascendiant Capital with a Buy rating and a specific price target of $2.6 suggests a positive outlook on Cyclo Therapeutics' stock. This analyst endorsement can lead to increased investor interest and potentially drive the stock price up in the short term, especially if the market perceives the analysis as credible and well-founded.